Multiple sclerosis - Novel insights and new therapeutic strategies

Current Opinion in Neurology

Volumn 18, Issue 3, 2005, Pages 211-220

  Kieseier, Bernd C ^a   Hemmer, Bernhard ^a   Hartung, Hans Peter ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

B lymphocytes; CD8; CIS; MOG; Natural history; Neutralizing antibodies; Pathology; Regulatory T cells

Indexed keywords

ALPHA4 INTEGRIN; BETA INTERFERON; CANNABINOID; CD8 ANTIGEN; CYCLOPHOSPHAMIDE; FINGOLIMOD; GLATIRAMER; HELIX LOOP HELIX PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; MINOCYCLINE; MITOXANTRONE; MONOCLONAL ANTIBODY; NATALIZUMAB; PLACEBO; RAZOXANE; SODIUM CALCIUM EXCHANGE PROTEIN; SODIUM CALCIUM EXCHANGE PROTEIN NAV1.6; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

BRAIN INJURY; CARDIOTOXICITY; CELL DEATH; HEART FAILURE; HUMAN; IMMUNOPATHOGENESIS; INFLAMMATION; LEUKEMIA; MULTIPLE SCLEROSIS; OLIGODENDROGLIA; PATHOGENESIS; REGULATORY MECHANISM; REMYELINIZATION; REVIEW; SIDE EFFECT; SODIUM CALCIUM EXCHANGE; SPASTICITY; STEM CELL TRANSPLANTATION; T LYMPHOCYTE;

EID: 20444457446     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.wco.0000169735.60922.fb     Document Type: Review

References (139)

1. Compston A, Coles A. Multiple sclerosis. Lancet 2002; 359:1221-1231.
2. Hemmer B, Kieseier B, Cepok S, Hartung HP. New immunopathologic insights into multiple sclerosis. Curr Neurol Neurosci Rep 2003; 3:246-255.
3. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000; 343:938-952.
4. Lucchinetti C, Brück W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000; 47:707-717.
5. Gold R, Hartung H-P, Toyka KV. Animal models for autoimmune demyelinating disorders of the nervous system. Mol Med Today 2000; 6:88-91.
6. Miller DH, Grossman RI, Reingold SC, McFarland HF. The role of magnetic resonance techniques in understanding and managing multiple sclerosis. Brain 1998; 121:3-24.
7. Kieseier BC, Hartung HP. Current disease-modifying therapies in multiple sclerosis. Semin Neurol 2003; 23:133-146.
8. Barnett MH, Prineas JW. Relapsing and remitting multiple sclerosis; pathology of the newly forming lesion. Ann Neurol 2004; 55:458-468. An exciting neuropathological study suggesting that oligodendrocyte death is the initial event in an acute MS relapse, whereas inflammation appears to be a secondary phenomenon only. This article underlines the issue of pathological heterogeneity in MS and adds further insights to this ongoing debate.
9. Trapp BD. Pathogenesis of multiple sclerosis: the eyes only see what the mind is prepared to comprehend. Ann Neurol 2004; 55:455-457.
10. Aboul-Enein F, Rauschka H, Kornek B, et al. Preferential loss of myelin-associated glycoprotein reflects hypoxia-like white matter damage in stroke and inflammatory brain diseases. J Neuropathol Exp Neurol 2003; 62:25-33.
11. Lassmann H, Bruck W, Lucchinetti C. Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol Med 2001; 7:115-121.
12. Lassmann H. Hypoxia-like tissue injury as a component of multiple sclerosis lesions. J Neurol Sci 2003; 206:187-191.
13. Selmaj K, Raine CS, Cross AH. Anti-tumor necrosis factor therapy abrogates autoimmune demyelination. Ann Neurol 1991; 30:694-700.
14. Hofman FM, Hinton DR, Johnson K, Merrill JE. Tumor necrosis factor identified in multiple sclerosis brain. J Exp Med 1989; 170:607-612.
15. Merrill JE, Ignarro U, Sherman MP, et al. Microglial cell cytotoxicity of oligodendrocytes is mediated through nitric oxide. J Immunol 1993; 151:2132-2141.
16. Maeda A, Sobel RA. Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions. J Neuropathol Exp Neurol 1996; 55:300-309.
17. Babbe H, Roers A, Waisman A, et al. Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J Exp Med 2000; 192:393-404.
18. Jacobsen M, Cepok S, Quak E, et al. Oligoclonal expansion of memory CD8+ T cells in cerebrospinal fluid from multiple sclerosis patients. Brain 2002; 125:538-550.
19. + cell clones persisted for more than 5 years in the cerebrospinal fluid and/or blood, potentially contributing to disease progression.
20. Neumann H, Medana IM, Bauer J, Lassmann H. Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases. Trends Neurosci 2002; 25:313-319.
21. Baecher-Allan C, Hafler DA. Suppressor T cells in human diseases. J Exp Med 2004; 200:273-276. This excellent review summarizes the scientific evidence accumulated over the past years on suppressor T cells, a functionally relevant subpopuiation of T lymphocytes, and their putative role in autoimmunity.
22. Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 2004; 199:971-979. With this elegant study the authors provide evidence that a functional decrease of regulatory T cells may account for autoimmunity in MS.
23. •] could not be confirmed by this study; thus further studies are needed to clarify this issue.
24. Takahashi K, Aranami T, Endoh M, et al. The regulatory role of natural killer cells in multiple sclerosis. Brain 2004; 127:1917-1927.
25. Serafini B, Rosicarelli B, Magliozzi R, et al. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol 2004; 14:164-174. In this immunohistochemical analysis the presence of B-cell follicles in the meninges of two cases with MS is demonstrated, supporting the concept of a critical role of B lymphocytes in the immunopathogenesis of MS.
26. Magliozzi R, Columba-Cabezas S, Serafini B, Aloisi F. Intracerebral expression of CXCL13 and BAFF is accompanied by formation of lymphoid follicle-like structures in the meninges of mice with relapsing experimental autoimmune encephalomyelitis. J Neuroimmunol 2004; 148:11-23.
27. Corcione A, Casazza S, Ferretti E, et al. Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis. Proc Natl Acad Sci USA 2004; 101:11064-11069.
28. Owens GP, Ritchie AM, Burgoon MP, et al. Single-cell repertoire analysis demonstrates that clonal expansion is a prominent feature of the B cell response in multiple sclerosis cerebrospinal fluid. J Immunol 2003; 171:2725-2733.
29. Ritchie AM, Gilden DH, Williamson RA, et al. Comparative analysis of the CD19+ and CD138+ cell antibody repertoires in the cerebrospinal fluid of patients with multiple sclerosis. J Immunol 2004; 173:649-656.
30. Monson NL, Brezinschek HP, Brezinschek RI, et al. Receptor revision and atypical mutational characteristics in clonally expanded B cells from the cerebrospinal fluid of recently diagnosed multiple sclerosis patients. J Neuroimmunol 2005; 158:170-181.
31. Prat A, Antel JP. Pathogenesis of multiple sclerosis. Curr Opin Neurol 2005, in press.
32. Arnett HA, Fancy SP, Alberta JA, et al. bHLH transcription factor Olig1 is required to repair demyelinated lesions in the CNS. Science 2004; 306:2111-2115. This carefully conducted study provides evidence that Olig1 function is required for brain repair. In animal models the genetic requirement for Olig1 in repairing types of CNS lesions similar to what is seen in MS patients is demonstrated. In MS lesions evidence is provided that Olig1 nuclear translocation may take place in the repair process, although functional data for the human CNS are not available.
33. Lubetzki C, Williams A, Stanhoff B. Promoting repair in multiple sclerosis. Curr Opin Neurol 2005, in press.
34. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. 1. Clinical course and disability. Brain 1989; 112:133-146.
35. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain 1989; 112:1419-1428.
36. Pittock SJ, Mayr WT, McClelland RL, et al. Disability profile of MS did not change over 10 years in a population-based prevalence cohort. Neurology 2004; 62:601-606. Study evaluating the clinical course of MS in a specific cohort of patients over a period of 10 years. The results suggest that the course of MS may be not as severe as estimated in specific patient cohorts.
37. •] patient survival was found to be reduced and some 30% of patients progressed to needing a cane or wheelchair or worse over the follow-up period of 10 years. However, most of the patients remained stable or progressed minimally. The authors were not able to identify specific factors predictive of worsening disability in this study.
38. Sundstrom P, Svenningsson A, Nystrom L, Forsgren L. Clinical characteristics of multiple sclerosis in Vasterbotten County in northern Sweden. J Neurol Neurosurg Psychiatry 2004; 75:711-716.
39. Wingerchuk DM, Weinshenker BG. The natural history of multiple sclerosis: implications for trial design. Curr Opin Neurol 1999; 12:345-349.
40. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000; 343:898-904.
41. Iannucci G, Tortorella C, Rovaris M, et al. Prognostic value of MR and magnetization transfer imaging findings in patients with clinically isolated syndromes suggestive of multiple sclerosis at presentation. Am J Neuroradiol 2000; 21:1034-1038.
42. Dalton CM, Brex PA, Miszkiel KA, et al. Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis. Ann Neurol 2002; 52:47-53.
43. Brex PA, Ciccarelli O, O'Riordan JI, et al. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002; 346: 158-164.
44. Beck RW, Trobe JD, Moke PS, et al. High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the optic neuritis treatment trial. Arch Ophthalmol 2003; 121:944-949.
45. Beck RW, Smith CH, Gal RL, et al. Neurologic impairment 10 years after optic neuritis. Arch Neurol 2004; 61:1386-1389.
46. Tintore M, Rovira A, Rio J, et al. Is optic neuritis more benign than other first attacks in multiple sclerosis? Ann Neurol 2005; 57:210-215.
47. Bielekova B, Martin R. Development of biomarkers in multiple sclerosis. Brain 2004; 127:1463-1478. Excellent review on biological surrogate markers in MS.
48. Teunissen CE, Dijkstra C, Polman C. Biological markers in CSF and blood for axonal degeneration in multiple sclerosis. Lancet Neurol 2005; 4:32-41.
49. Berger T, Rubner P, Schautzer F, et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med 2003; 349:139-145.
50. Antel JP, Bar-Or A. Do myelin-directed antibodies predict multiple sclerosis? N Engl J Med 2003; 349:107-109.
51. Karni A, Bakimer-Kleiner R, Abramsky O, Ben-Nun A. Elevated levels of antibody to myelin oligodendrocyte glycoprotein is not specific for patients with multiple sclerosis. Arch Neurol 1999; 56:311-315.
52. Gaertner S, de Graaf KL, Greve B, Weissert R. Antibodies against glycosylated native MOG are elevated in patients with multiple sclerosis. Neurology 2004; 63:2381-2383.
53. Lampasona V, Franciotta D, Furlan R, et al. Similar low frequency of anti-MOG IgG and IgM in MS patients and healthy subjects. Neurology 2004; 62:2092-2094.
54. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004; 364:2106-2112. In this study the authors describe a surrogate marker that differentiates neuromyelitis optica from MS with high specificity.
55. Munch M, Hvas J, Christensen T, et al. The implications of Epstein-Barr virus in multiple sclerosis - a review. Acta Neurol Scand Suppl 1997; 169:59-64.
56. Hollsberg P, Hansen HJ, Haahr S. Altered CD8+ T cell responses to selected Epstein-Barr virus immunodominant epitopes in patients with multiple sclerosis. Clin Exp Immunol 2003; 132:137-143.
57. Wagner HJ, Munger KL, Ascherio A. Plasma viral load of Epstein-Barr virus and risk of multiple sclerosis. Eur J Neurol 2004; 11:833-834.
58. Holmoy T, Kvale EO, Vartdal F. Cerebrospinal fluid CD4+ T cells from a multiple sclerosis patient cross-recognize Epstein-Barr virus and myelin basic protein. J Neurovirol 2004; 10:278-283.
59. Alotaibi S, Kennedy J, Tellier R, et al. Epstein-Barr virus in pediatric multiple sclerosis. JAMA 2004; 291:1875-1879.
60. Ponsonby AL, van der Mei I, Dwyer T, et al. Exposure to infant siblings during early life and risk of multiple sclerosis. JAMA 2005; 293:463-469. In this study among 408 people studied in Australia, a history of exposure to an infant sibling in the first 6 years of life was associated with a reduced risk of developing MS. The authors suggest that exposure to infections early in life may alter immune activity and decrease the risk of developing an immune-mediated disorder such as MS.
61. Alvarez-Lafuente R, De las Heras V, et al. Relapsing-remitting multiple sclerosis and human herpesvirus 6 active infection. Arch Neurol 2004; 61:1523-1527.
62. Opsahl ML, Kennedy PGE. Early and late HHV-6 gene transcripts in multiple sclerosis lesions and normal appearing white matter. Brain 2005, in press.
63. Antony JM, van Marie G, Opii W, et al. Human endogenous retrovirus glycoprotein-mediated induction of redox reactants causes oligodendrocyte death and demyelination. Nat Neurosci 2004; 7:1088-1095.
64. Panitch H, Miller A, Paty D, Weinshenker B. Interferon beta-1b in secondary progressive MS, results from a 3-year controlled study. Neurology 2004; 63:1788-1795.
65. Kappos L, Weinshenker B, Pozzilli C, et al. Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials. Neurology 2004; 63:1779-1787. Long-awaited comparative and explanatory analysis of the two interferon β-1b trials in SPMS, since both trials closed with divergent results (see [64]).
66. Schellekens H. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov 2002; 1:457-462.
67. Hartung HP, Munschauer 3rd. FE. Assessment and management of neutralizing antibodies in patients with multiple sclerosis. J Neurol 2004; 251(suppl 2):II40-II42.
68. PRISMS Study Group. PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001; 56:1628-1636.
69. Sorensen PS, Ross C, Clemmesen KM, et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 2003; 362:1184-1191.
70. Sorensen PS, Koch-Henriksen N, Ross C, et al. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology 2005, in press.
71. Farina C, Vargas V, Heydari N, er al. Treatment with glatiramer acetate induces specific IgG4 antibodies in multiple sclerosis patients. J Neuroimmunol 2002; 123:188-192.
72. Salama HH, Hong J, Zang YC, et al. Blocking effects of serum reactive antibodies induced by glatiramer acetate treatment in multiple sclerosis. Brain 2003; 126:2638-2647.
73. Teitelbaum D, Brenner T, Abramsky O, et al. Antibodies to glatiramer acetate do not interfere with its biological functions and therapeutic efficacy. Mult Scler 2003; 9:592-599.
74. Karni A, Balashov K, Hancock WW, et al. Cyclophosphamide modulates CD4+ T cells into a T helper type 2 phenotype and reverses increased IFN-gamma production of CD8+ T cells in secondary progressive multiple sclerosis. J Neuroimmunol 2004; 146:189-198.
75. Weiner HL, Mackin GA, Orav EJ, et al. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology 1993; 43:910-918.
76. The Canadian Cooperative Multiple Sclerosis Study Group. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet 1991; 337:441-446.
77. Zephir H, de Seze J, Duhamel A, et al. Treatment of progressive forms of multiple sclerosis by cyclophosphamide: a cohort study of 490 patients. J Neurol Sci 2004; 218:73-77.
78. Perini P, Gallo P. Cyclophosphamide is effective in stabilizing rapidly deteriorating secondary progressive multiple sclerosis. J Neurol 2003; 250:834-838.
79. Portaccio E, Zipoli V, Siracusa G, et al. Safety and tolerability of cyclophosphamide 'pulses' in multiple sclerosis: a prospective study in a clinical cohort. Mult Scler 2003; 9:446-450.
80. Hartung HP, Gonsette R, Konig N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002; 360:2018-2025.
81. Edan G, Miller D, Clanet M, et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 1997; 62:112-118.
82. Goodin DS, Arnason BG, Coyle PK, et al. The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2003; 61:1332-1338.
83. Ghalie RG, Edan G, Laurent M, et al. Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS. Neurology 2002; 59:909-913.
84. Spindler M, Weilbach F, Beer M, et al. Non-invasive functional and biochemical assessment of mitoxantrone cardiotoxicity in patients with multiple sclerosis. J Cardiovasc Pharmacol 2003; 42:680-687.
85. Weilbach FX, Chan A, Toyka KV, Gold R. The cardioprotector dexrazoxane augments therapeutic efficacy of mitoxantrone in experimental autoimmune encephalomyelitis. Clin Exp Immunol 2004; 135:49-55.
86. Brassat D, Recher C, Waubant E, et al. Therapy-related acute myeloblastic leukemia after mitoxantrone treatment in a patient with MS. Neurology 2002; 59:954-955.
87. Cattaneo C, Almici C, Borlenghi E, et al. A case of acute promyelocytic leukaemia following mitoxantrone treatment of multiple sclerosis. Leukemia 2003; 17:985-986.
88. Delisse B, de Seze J, Mackowiak A, et al. Therapy related acute myeloblastic leukaemia after mitoxantrone treatment in a patient with multiple sclerosis. Mult Scler 2004; 10:92.
89. Heesen C, Bruegmann M, Gbdamosi J, et al. Therapy-related acute myelogenous leukaemia (t-AML) in a patient with multiple sclerosis treated with mitoxantrone. Mult Scler 2003; 9:213-214.
90. Jaster JH, Niell HB, Dohan Jr. FC, Smith TW. Therapy-related acute myeloblastic leukemia after mitoxantrone treatment in a patient with MS. Neurology 2003; 60:1399-1400.
91. Novoselac AV, Reddy S, Sanmugarajah J, Acute promyelocytic leukemia in a patient with multiple sclerosis following treatment with mitoxantrone. Leukemia 2004; 18:1561-1562.
92. Tanasescu R, Debouverie M, Pittion S, et al. Acute myeloid leukaemia induced by mitoxantrone in a multiple sclerosis patient. J Neurol 2004; 251:762-763.
93. Vicari AM, Ciceri F, Folli F, et al. Acute promyelocytic leukemia following mitoxantrone as single agent for the treatment of multiple sclerosis. Leukemia 1998; 12:441-442.
94. Voltz R, Starck M, Zingler V, et al. Mitoxantrone therapy in multiple sclerosis and acute leukaemia: a case report out of 644 treated patients. Mult Scler 2004; 10:472-474.
95. Ghalie RG, Mauch E, Edan G, et al. A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis. Mult Scler 2002; 8:441-445.
96. Chan A, Weilbach FX, Toyka KV, Gold R. Mitoxantrone induces celt death in peripheral blood leucocytes of multiple sclerosis patients. Clin Exp Immunol 2005; 139:152-158. This study carefully analyzed the effect of mitoxantrone on immunocompetent cells ex vivo. Mitoxantrone was found to be incorporated rapidly in circulating cells of MS patients and to induce a pronounced suppression of proliferative responses. This immunosuppression appeared to be mediated by the induction of late apoptotic/necrotic cell death with a preferential susceptibility of B cells.
97. Neuhaus O, Wiendl H, Kieseier BC, et al. Multiple sclerosis: mitoxantrone promotes differential effects on immunocompetent cells in vitro. J Neuroimmunol 2005, in press.
98. Baker D, Pryce G, Croxford JL, et al. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 2000; 404:84-87.
99. Zajicek J, Fox P, Sanders H, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 2003; 362:1517-1526.
100. Killestein J, Uitdehaag BM, Polman CH. Cannabinoids in multiple sclerosis: do they have a therapeutic role? Drugs 2004; 64:1-11.
101. Pryce G, Ahmed Z, Hankey DJ, et al. Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain 2003; 126:2191-2202.
102. Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003; 348:15-23. In this phase II study 213 patients with relapsing forms of MS were randomized to receive 3 mg of intravenous natalizumab/kg of body weight (68 patients), 6 mg/kg (74 patients), or placebo (71 patients) every 28 days for 6 months. The primary end point was the number of new brain lesions on monthly gadolinium-enhanced MRI during the 6-month treatment period. Treatment with natalizumab led to fewer inflammatory brain lesions and fewer relapses over this period of time. The results of this study paved the way for the still-ongoing two phase III trials, which, after first analysis, let the FDA to licence natalizumab for relapsing forms of MS.
103. von Andrian UH, Engelhardt B. Alpha4 integrins as therapeutic targets in autoimmune disease. N Engl J Med 2003; 348:68-72. Natalizumab is effective in preventing the invasion of immunocompetent cells across the blood-brain barrier. This editorial discusses the immunological basis for therapeutic approaches using antibodies against adhesion molecules.
104. O'Connor PW, Goodman A, Willmer-Hulme AJ, et al. Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects. Neurology 2004; 62:2038-2043. In this randomized, double-blind, multicenter trial, the effects of a single dose of natalizumab administered soon after the onset of MS relapses were assessed in 180 MS patients. This single dose did not hasten clinical recovery after relapse, although a significant decrease in gadolinium-enhancing lesion volume was observed at 1 and 3 weeks after treatment, suggesting that once the blood-brain barrier is damaged natalizumab appears to be clinically ineffective.
105. Stuve O, Prod'homme T, Youssef S, et al. Statins as potential therapeutic agents in multiple sclerosis. Curr Neurol Neurosci Rep 2004; 4:237-244.
106. Stuve O, Youssef S, Steinman L, Zamvil SS. Statins as potential therapeutic agents in neuroinflammatory disorders. Curr Opin Neurol 2003; 16:393-401.
107. Math N, Giri S, Prasad R, et al. Potential targets of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor for multiple sclerosis therapy. J Immunol 2004; 172:1273-1286.
108. Neuhaus O, Archelos JJ, Hartung HP. Stalins in multiple sclerosis: a new therapeutic option? Mult Scler 2003; 9:429-430.
109. Neuhaus O, Stuve O, Zamvil SS, Hartung HP. Are statins a treatment option for multiple sclerosis? Lancet Neurol 2004; 3:369-371.
110. Greenwood J, Walters CE, Pryce G, et al. Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis. FASEB J 2003; 17:905-907.
111. Youssef S, Stuve O, Patarroyo JC, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002; 420:78-84.
112. Vollmer T, Key L, Durkalski V, et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 2004; 363:1607-1608. The first study in RRMS suggesting that statins may exhibit a positive effect as determined by MRI measures. Given the small number of patients studied, large-scale, double-blind, placebo-controlled trials are warranted to determine the therapeutic potential of statins in MS.
113. Yopp AC, Fu S, Honig SM, et al. FTY720-enhanced T cell homing is dependent on CCR2, CCR5, CCR7, and CXCR4: evidence for distinct chemokine compartments. J Immunol 2004; 173:855-865.
114. Muller H, Hofer S, Kaneider N, et al. The immunomodulator FTY720 interferes with effector functions of human monocyte-derived dendritic cells. Eur J Immunol 2005.
115. Fujino M, Funeshima N, Kitazawa Y, et al. Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment. J Pharmacol Exp Ther 2003; 305:70-77.
116. Webb M, Tham CS, Lin FF, et al. Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice. J NeuroImmunol 2004; 153:108-121.
117. Yong VW, Wells J, Giuliani F, et al. The promise of minocycline in neurology. Lancet Neurol 2004; 3:744-751. A thorough overview of the potential of minocycline in neurology. Given the broad spectrum of effects induced by this drug inflammatory as well as neurodegenerative diseases appear to be suitable targets for therapeutic application with minocycline.
118. Metz LM, Zhang Y, Yeung M, et al. Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann Neurol 2004; 55:756.
119. Li WW, Setzu A, Zhao C, Franklin PJ. Minocycline-mediated inhibition of microglia activation impairs oligodendrocyte progenitor cell responses and remyelination in a non-immune model of demyelination. J Neuroimmunol 2005; 158:58-66.
120. Blanco Y, Saiz A, Carreras E, Graus F. Autologous haematopoietic-stem- cell transplantation for multiple sclerosis. Lancet Neurol 2005; 4:54-63.
121. Rose JW, Watt HE, White AT, Carlson NG. Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody. Ann Neurol 2004; 56:864-867.
122. Bielekova B, Richert N, Howard T, et al. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci USA 2004; 101:8705-8708.
123. Glabinski AR, Bielecki B, Kawczak JA, et al. Treatment with soluble tumor necrosis factor receptor (sTNFR):Fc/p80 fusion protein ameliorates relapsing-remitting experimental autoimmune encephalomyelitis and decreases chemokine expression. Autoimmunity 2004; 37:465-471.
124. Barbar E, Rola-Pleszczynski M, Payet MD, Dupuis G. Protein kinase C inhibits the transplasma membrane influx of Ca2+ triggered by 4-aminopyridine in Jurkat T lymphocytes. Biochim Biophys Acta 2003; 1622:89-98.
125. Wulff H, Beeton C, Chandy KG. Potassium channels as therapeutic targets for autoimmune disorders. Curr Opin Drug Disc Dev 2003; 6:640-647.
126. Wulff H, Calabresi PA, Allie R, et al. The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS. J Clin Invest 2003; 111:1703-1713.
127. Craner MJ, Hains BC, Lo AC, et al. Co-localization of sodium channel Nav1.6 and the sodium-calcium exchanger at sites of axonal injury in the spinal cord in EAE. Brain 2004; 127:294-303.
128. Craner MJ, Newcombe J, Black JA, et al. Molecular changes in neurons in MS: altered axonal expression of NAv1.2 and Nav1.6 sodium channals and Na+/Ca2+ exchanger. Proc Nat Acad Sci USA 2004; 101:3168-8173.
129. Bechtold DA, Kapoor R, Smith KJ. Axonal protection using flecainide in experimental autoimmune encephalomyelitis. Ann Neurol 2004; 55:607-616.
130. Waxman SG. Sodium channel blockers and axonal protection in neuroinflammatory disease. Brain 2005; 128:5-6.
131. Killestein J, Polman CH. Current trials in MS - established evidence and future hopes. Curr Opin Neurol 2005, in press.
132. Hohlfeld R, Wekerle H. Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines. Proc Natl Acad Sci USA 2004; 101(suppl 2):14599-14606. A thorough overview on ongoing therapeutic strategies in MS.
133. Selzer ME. Promotion of axonal regeneration in the injured CNS. Lancet Neurol 2003; 2:157-166.
134. Fernandez M, Giuliani A, Pirondi S, et al. Thyroid hormone administration enhances remyelination in chronic demyelinating inflammatory disease. Proc Natl Acad Sci USA 2004; 101:16363-16368.
135. Penderis J, Shields SA, Franklin RJ. Impaired remyelination and depletion of oligodendrocyte progenitors does not occur following repeated episodes of focal demyelination in the rat central nervous system. Brain 2003; 126:1382-1391.
136. Rice CM, Scolding NJ. Adult stem cells - reprogramming neurological repair? Lancet 2004; 364:193-199.
137. Pluchino S, Furlan R, Martino G. Cell-based remyelinating therapies in multiple sclerosis: evidence from experimental studies. Curr Opin Neurol 2004; 17:247-255.
138. Chien KR. Stem cells: lost in translation. Nature 2004; 428:607-608. A critical review on the stem-cell hype.
139. Wiendl H, Kieseier BC. Disease modifying therapies in multiple sclerosis: an update on recent and ongoing trials and future strategies. Exp Opin Inv Drugs 2003; 12:689-712.